46,253 Shares in INmune Bio, Inc. (NASDAQ:INMB) Acquired by XTX Topco Ltd

XTX Topco Ltd purchased a new stake in INmune Bio, Inc. (NASDAQ:INMB) in the 3rd quarter, HoldingsChannel.com reports. The institutional investor purchased 46,253 shares of the company’s stock, valued at approximately $249,000.

Several other large investors have also recently modified their holdings of INMB. Praetorian PR LLC increased its holdings in INmune Bio by 61.0% in the third quarter. Praetorian PR LLC now owns 780,800 shares of the company’s stock valued at $4,209,000 after purchasing an additional 295,800 shares during the period. CVI Holdings LLC acquired a new position in shares of INmune Bio in the second quarter worth approximately $5,260,000. State Street Corp boosted its holdings in INmune Bio by 35.1% in the third quarter. State Street Corp now owns 226,428 shares of the company’s stock valued at $1,220,000 after acquiring an additional 58,838 shares during the last quarter. Marshall Wace LLP increased its position in INmune Bio by 332.1% during the 2nd quarter. Marshall Wace LLP now owns 115,916 shares of the company’s stock valued at $1,022,000 after purchasing an additional 89,091 shares during the period. Finally, Bank of New York Mellon Corp raised its holdings in INmune Bio by 124.6% during the 2nd quarter. Bank of New York Mellon Corp now owns 58,600 shares of the company’s stock worth $517,000 after purchasing an additional 32,511 shares during the last quarter. Institutional investors own 12.72% of the company’s stock.

Analyst Upgrades and Downgrades

INMB has been the subject of several recent analyst reports. Scotiabank assumed coverage on shares of INmune Bio in a research report on Thursday, August 22nd. They set a “sector outperform” rating and a $22.00 price objective for the company. Raymond James initiated coverage on INmune Bio in a research report on Friday, September 27th. They issued an “outperform” rating and a $18.00 price objective for the company. Finally, Alliance Global Partners started coverage on INmune Bio in a research note on Monday, October 21st. They issued a “buy” rating and a $20.00 price target on the stock.

Insider Transactions at INmune Bio

In other INmune Bio news, CFO David J. Moss purchased 10,000 shares of the firm’s stock in a transaction on Monday, September 30th. The stock was acquired at an average price of $5.29 per share, for a total transaction of $52,900.00. Following the purchase, the chief financial officer now owns 1,285,869 shares of the company’s stock, valued at $6,802,247.01. This trade represents a 0.78 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 35.20% of the stock is owned by insiders.

INmune Bio Trading Down 8.2 %

INMB opened at $4.57 on Thursday. The company has a market cap of $101.33 million, a P/E ratio of -2.10 and a beta of 1.79. The company has a fifty day moving average price of $5.31 and a two-hundred day moving average price of $6.58. INmune Bio, Inc. has a 1-year low of $4.45 and a 1-year high of $14.74.

INmune Bio (NASDAQ:INMB) last posted its quarterly earnings results on Thursday, October 31st. The company reported ($0.60) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.11). INmune Bio had a negative return on equity of 117.48% and a negative net margin of 26,333.59%. During the same period last year, the company earned ($0.48) EPS. On average, research analysts forecast that INmune Bio, Inc. will post -2.24 EPS for the current fiscal year.

About INmune Bio

INmune Bio, Inc, a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation.